GT Biopharma, Inc.
GTBP
$0.61
-$0.15-19.57%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.11M | -1.43M | -776.00K | -3.78M | -3.41M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 147.00K | -1.04M | -123.00K | 77.00K | -93.00K |
| Change in Net Operating Assets | -710.00K | -545.00K | -1.30M | 1.23M | 767.00K |
| Cash from Operations | -3.68M | -3.01M | -2.20M | -2.47M | -2.74M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 1.00K | -1.00K |
| Cash from Investing | -- | -- | -- | 1.00K | -1.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 436.00K | 616.00K | 0.00 | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 1.06M | 5.44M | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -85.00K | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 977.00K | 5.88M | 616.00K | 0.00 | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.70M | 2.86M | -1.59M | -2.47M | -2.74M |